|
1
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hofmann M, Stoss O, Shi D, Büttner R, van
de Vijver M, Kim W, Ochiai A, Rüschoff J and Henkel T: Assessment
of a HER2 scoring system for gastric cancer: Results from a
validation study. Histopathology. 52:797–805. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang J, Luo H, Li Y, Li J, Cai Z, Su X,
Dai D, Du W, Chen T and Chen M: Intratumoral heterogeneity
determines discordant results of diagnostic tests for human
epidermal growth factor receptor (HER) 2 in gastric cancer
specimens. Cell Biochem Biophys. 62:221–228. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee HE, Park KU, Yoo SB, Nam SK, do Park
J, Kim HH and Lee HS: Clinical significance of intratumoral HER2
heterogeneity in gastric cancer. Eur J Cancer. 49:1448–1457. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rüschoff J, Hanna W, Bilous M, Hofmann M,
Osamura RY, Penault-Llorca F, van de Vijver M and Viale G: HER2
testing in gastric cancer: A practical approach. Mod Pathol.
25:637–650. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang D, Lu N, Fan Q, Sheng W, Bu H, Jin
X, Li G, Liu Y, Li X, Sun W, et al: HER2 status in gastric and
gastroesophageal junction cancer assessed by local and central
laboratories: Chinese results of the HER-EAGLE study. PLoS One.
8:e802902013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kushima R, Kuwata T, Yao T, Kuriki H,
Hashizume K, Masuda S, Tsuda H and Ochiai A: Interpretation of HER2
tests in gastric cancer: Confirmation of interobserver differences
and validation of a QA/QC educational program. Virchows Arch.
464:539–545. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Carney WP, Neumann R, Lipton A, Leitzel K,
Ali S and Price CP: Monitoring the circulating levels of the
HER2/neu oncoprotein in breast cancer. Clin Breast Cancer.
5:105–116. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fornier MN, Seidman AD, Schwartz MK, Ghani
F, Thiel R, Norton L and Hudis C: Serum HER2 extracellular domain
in metastatic breast cancer patients treated with weekly
trastuzumab and paclitaxel: Association with HER2 status by
immunohistochemistry and fluorescence in situ hybridization and
with response rate. Ann Oncol. 16:234–239. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Finn RS, Gagnon R, Di Leo A, Press MF,
Arbushites M and Koehler M: Prognostic and predictive value of HER2
extracellular domain in metastatic breast cancer treated with
lapatinib and paclitaxel in a randomized phase III study. J Clin
Oncol. 27:5552–5558. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lennon S, Barton C, Banken L, Gianni L,
Marty M, Baselga J and Leyland-Jones B: Utility of serum HER2
extracellular domain assessment in clinical decision making: Pooled
analysis of four trials of trastuzumab in metastatic breast cancer.
J Clin Oncol. 27:1685–1693. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Leary AF, Hanna WM, van de Vijver MJ,
Penault-Llorca F, Rüschoff J, Osamura RY, Bilous M and Dowsett M:
Value and limitations of measuring HER-2 extracellular domain in
the serum of breast cancer patients. J Clin Oncol. 27:1694–1705.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kontani K, Kuroda N, Hashimoto S, Murazawa
C, Norimura S, Tanaka H, Ohtani M, Fujiwara-Honjo N, Kushida Y,
Date M, et al: Clinical usefulness of human epidermal growth factor
receptor-2 extracellular domain as a biomarker for monitoring
cancer status and predicting the therapeutic efficacy in breast
cancer. Cancer Biol Ther. 14:20–28. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Borrmann R: Geschwülste des Magens und
Duodenums, Makroskopische Formen. Henke u. Lubarsch. Handbuch d.
sp. Path. usw., 1/IV. 864–871. 1926.
|
|
15
|
Saito M, Yamashita K, Arimura Y, Kaneto H,
Okuda H, Nojima M, Hagiwara T, Suzuki K, Adachi T, Goto A, et al:
Serum HER2 as an adjunct to assess HER2 status for advanced gastric
cancer: A prospective multicenter trial (SHERLOCK). Acta Oncol.
55:309–17. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
National Cancer Institute: Common
Terminology Criteria for Adverse Events (CTCAE). Version 4.0.
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdfAccessed.
January 05–2014
|
|
17
|
Gravalos C and Jimeno A: HER2 in gastric
cancer: A new prognostic factor and a novel therapeutic target. Ann
Oncol. 19:1523–1529. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hofmann M, Stoss O, Shi D, Büttner R, van
de Vijver M, Kim W, Ochiai A, Rüschoff J and Henkel T: Assessment
of a HER2 scoring system for gastric cancer: Results from a
validation study. Histopathology. 52:797–805. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tanner M, Hollmén M, Junttila TT, Kapanen
AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, et al:
Amplification of HER-2 in gastric carcinoma: Association with
Topoisomerase IIalpha gene amplification, intestinal type, poor
prognosis and sensitivity to trastuzumab. Ann Oncol. 16:273–278.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dai SQ, An X, Wang F, Shao Q, Chen YC,
Kong YN, Chen C, Li C, Luo HY, Liang Y, et al: Serum HER 2
extracellular domain level is correlated with tissue HER 2 status
in metastatic gastric or gastro-oesophageal junction
adenocarcinoma. PloS One. 8:e634582013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Narita T, Seshimo A, Suzuki M, Murata J
and Kameoka S: Status of tissue expression and serum levels of HER2
in gastric cancer patients in japan. Hepatogastroenterology.
60:1083–1088. 2013.PubMed/NCBI
|
|
22
|
Oyama K, Fushida S, Tsukada T, Kinoshita
J, Watanabe T, Shoji M, Nakanuma S, Okamoto K, Sakai S, Makino I,
et al: Evaluation of serum HER2-ECD levels in patients with gastric
cancer. J Gastroenterol. 50:41–45. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Leyland-Jones B and Smith BR: Serum HER2
testing in patients with HER2-positive breast cancer: The death
knell tolls. Lancet Oncol. 12:286–295. 2011. View Article : Google Scholar : PubMed/NCBI
|
